Fractional Flow Reserve-Guided Multivessel Angioplasty in Myocardial Infarction
- PMID: 28317428
- DOI: 10.1056/NEJMoa1701067
Fractional Flow Reserve-Guided Multivessel Angioplasty in Myocardial Infarction
Abstract
Background: In patients with ST-segment elevation myocardial infarction (STEMI), the use of percutaneous coronary intervention (PCI) to restore blood flow in an infarct-related coronary artery improves outcomes. The use of PCI in non-infarct-related coronary arteries remains controversial.
Methods: We randomly assigned 885 patients with STEMI and multivessel disease who had undergone primary PCI of an infarct-related coronary artery in a 1:2 ratio to undergo complete revascularization of non-infarct-related coronary arteries guided by fractional flow reserve (FFR) (295 patients) or to undergo no revascularization of non-infarct-related coronary arteries (590 patients). The FFR procedure was performed in both groups, but in the latter group, both the patients and their cardiologist were unaware of the findings on FFR. The primary end point was a composite of death from any cause, nonfatal myocardial infarction, revascularization, and cerebrovascular events at 12 months. Clinically indicated elective revascularizations performed within 45 days after primary PCI were not counted as events in the group receiving PCI for an infarct-related coronary artery only.
Results: The primary outcome occurred in 23 patients in the complete-revascularization group and in 121 patients in the infarct-artery-only group that did not receive complete revascularization, a finding that translates to 8 and 21 events per 100 patients, respectively (hazard ratio, 0.35; 95% confidence interval [CI], 0.22 to 0.55; P<0.001). Death occurred in 4 patients in the complete-revascularization group and in 10 patients in the infarct-artery-only group (1.4% vs. 1.7%) (hazard ratio, 0.80; 95% CI, 0.25 to 2.56), myocardial infarction in 7 and 28 patients, respectively (2.4% vs. 4.7%) (hazard ratio, 0.50; 95% CI, 0.22 to 1.13), revascularization in 18 and 103 patients (6.1% vs. 17.5%) (hazard ratio, 0.32; 95% CI, 0.20 to 0.54), and cerebrovascular events in 0 and 4 patients (0 vs. 0.7%). An FFR-related serious adverse event occurred in 2 patients (both in the group receiving infarct-related treatment only).
Conclusions: In patients with STEMI and multivessel disease who underwent primary PCI of an infarct-related artery, the addition of FFR-guided complete revascularization of non-infarct-related arteries in the acute setting resulted in a risk of a composite cardiovascular outcome that was lower than the risk among those who were treated for the infarct-related artery only. This finding was mainly supported by a reduction in subsequent revascularizations. (Funded by Maasstad Cardiovascular Research and others; Compare-Acute ClinicalTrials.gov number, NCT01399736 .).
Comment in
-
Acute coronary syndromes: Complete revascularization for STEMI.Nat Rev Cardiol. 2017 Apr 11;14(5):254-255. doi: 10.1038/nrcardio.2017.55. Nat Rev Cardiol. 2017. PMID: 28397848 No abstract available.
-
Fractional Flow Reserve-Guided Multivessel Angioplasty in Myocardial Infarction.N Engl J Med. 2017 Jul 27;377(4):397. doi: 10.1056/NEJMc1706275. N Engl J Med. 2017. PMID: 28745982 No abstract available.
-
Fractional Flow Reserve–Guided Multivessel Angioplasty in Myocardial Infarction.N Engl J Med. 2017 Jul 27;377(4):396-7. doi: 10.1056/NEJMc1706275. N Engl J Med. 2017. PMID: 28748687 No abstract available.
-
The Compare-Acute trial of fractional flow reserve-guided multivessel angioplasty in myocardial infarction.EuroIntervention. 2017 Aug 4;13(5):e613-e616. doi: 10.4244/EIJV13I5A96. EuroIntervention. 2017. PMID: 28781251 No abstract available.
Similar articles
-
Fractional Flow Reserve-Guided Complete Revascularization Improves the Prognosis in Patients With ST-Segment-Elevation Myocardial Infarction and Severe Nonculprit Disease: A DANAMI 3-PRIMULTI Substudy (Primary PCI in Patients With ST-Elevation Myocardial Infarction and Multivessel Disease: Treatment of Culprit Lesion Only or Complete Revascularization).Circ Cardiovasc Interv. 2017 Apr;10(4):e004460. doi: 10.1161/CIRCINTERVENTIONS.116.004460. Circ Cardiovasc Interv. 2017. PMID: 28404623 Clinical Trial.
-
FFR-Guided Complete or Culprit-Only PCI in Patients with Myocardial Infarction.N Engl J Med. 2024 Apr 25;390(16):1481-1492. doi: 10.1056/NEJMoa2314149. Epub 2024 Apr 8. N Engl J Med. 2024. PMID: 38587995 Clinical Trial.
-
Multivessel PCI Guided by FFR or Angiography for Myocardial Infarction.N Engl J Med. 2021 Jul 22;385(4):297-308. doi: 10.1056/NEJMoa2104650. Epub 2021 May 16. N Engl J Med. 2021. PMID: 33999545 Clinical Trial.
-
Survival After Varying Revascularization Strategies in Patients With ST-Segment Elevation Myocardial Infarction and Multivessel Coronary Artery Disease: A Pairwise and Network Meta-Analysis.JACC Cardiovasc Interv. 2016 Sep 12;9(17):1765-76. doi: 10.1016/j.jcin.2016.06.012. JACC Cardiovasc Interv. 2016. PMID: 27609250 Review.
-
Complete or Culprit-Only Revascularization for Patients With Multivessel Coronary Artery Disease Undergoing Percutaneous Coronary Intervention: A Pairwise and Network Meta-Analysis of Randomized Trials.JACC Cardiovasc Interv. 2017 Feb 27;10(4):315-324. doi: 10.1016/j.jcin.2016.11.047. JACC Cardiovasc Interv. 2017. PMID: 28231899 Review.
Cited by
-
Management of Acute Coronary Syndrome in Elderly Patients: A Narrative Review through Decisional Crossroads.J Clin Med. 2024 Oct 10;13(20):6034. doi: 10.3390/jcm13206034. J Clin Med. 2024. PMID: 39457985 Free PMC article. Review.
-
Functional and morphological improvement of significant non-culprit coronary artery stenosis by LDL-C reduction with a PCSK9 antibody: Rationale and design of the randomized FITTER trial.Heliyon. 2024 Sep 18;10(19):e38077. doi: 10.1016/j.heliyon.2024.e38077. eCollection 2024 Oct 15. Heliyon. 2024. PMID: 39430462 Free PMC article.
-
The role of chronic total occlusions in non-infarct-related arteries in acute coronary syndrome patients: a systematic review.Future Cardiol. 2024;20(10):581-590. doi: 10.1080/14796678.2024.2406651. Epub 2024 Oct 9. Future Cardiol. 2024. PMID: 39382445 Review.
-
Role of physiology in the management of multivessel disease among patients with acute coronary syndrome.AsiaIntervention. 2024 Sep 27;10(3):157-168. doi: 10.4244/AIJ-D-24-00051. eCollection 2024 Sep. AsiaIntervention. 2024. PMID: 39347110 Free PMC article. Review.
-
Impact of the completeness of revascularization and high bleeding risk status in acute coronary syndrome patients with multi-vessel disease: A retrospective analysis.JRSM Cardiovasc Dis. 2024 Sep 17;13:20480040241283152. doi: 10.1177/20480040241283152. eCollection 2024 Jan-Dec. JRSM Cardiovasc Dis. 2024. PMID: 39346685 Free PMC article.
Publication types
MeSH terms
Associated data
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous